Antimalarial pharmacokinetics and treatment regimens.

The sheer numbers of people infected with malaria (approximately 200 million), and the annual death toll (one to two million) make this the most important parasitic disease of man. As a consequence antimalarial drugs are consumed on a vast scale in tropical areas of the world (WHO, 1990a). Indeed it has been suggested that the majority of the population in sub-saharan Africa has detectable blood chloroquine concentrations potentially

[1]  T. Hien,et al.  An open randomized comparison of intravenous and intramuscular artesunate in severe falciparum malaria. , 1992, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[2]  A. Breckenridge,et al.  Interaction of arteether with the red blood cell in‐vitro and its possible importance in the interpretation of plasma concentrations in‐vivo , 1992, The Journal of pharmacy and pharmacology.

[3]  K. Marsh,et al.  The disposition of oral and intramuscular pyrimethamine/sulphadoxine in Kenyan children with high parasitaemia but clinically non-severe falciparum malaria. , 1992, British journal of clinical pharmacology.

[4]  L. Scheibel.  WHO Model Prescribing Information, Drugs Used in Parasitic Diseases , 1991 .

[5]  F. Nosten,et al.  Mefloquine for multidrug-resistant malaria , 1991, The Lancet.

[6]  K. Silamut,et al.  Alpha 1-acid glycoprotein (orosomucoid) and plasma protein binding of quinine in falciparum malaria. , 1991, British journal of clinical pharmacology.

[7]  M. Trautmann,et al.  Neuropsychiatric side effects after the use of mefloquine. , 1991, The American journal of tropical medicine and hygiene.

[8]  R. Steffen,et al.  Malaria chemoprophylaxis with mefloquine , 1991, The Lancet.

[9]  A. Breckenridge,et al.  The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study. , 1991, British journal of clinical pharmacology.

[10]  H. Webster,et al.  Mefloquine-resistant falciparum malaria on the Thai-Burmese border , 1991, The Lancet.

[11]  N. White,et al.  Mefloquine pharmacokinetics and resistance in children with acute falciparum malaria. , 1991, British journal of clinical pharmacology.

[12]  J. Bras,et al.  Efficacy of a loading dose of oral chloroquine in a 36-hour treatment schedule for uncomplicated plasmodium falciparum malaria , 1991, Antimicrobial Agents and Chemotherapy.

[13]  N. White,et al.  Clinical Pharmacokinetics of Mefloquine , 1990, Clinical pharmacokinetics.

[14]  O. Walker,et al.  Parenteral sulphadoxine-pyrimethamine (Fansidar): an effective and safe but under-used method of anti-malarial treatment. , 1990, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[15]  D. Kwiatkowski,et al.  The pharmacokinetic properties of intramuscular quinine in Gambian children with severe falciparum malaria. , 1990, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[16]  N. White,et al.  Mefloquine antimalarial prophylaxis in pregnancy: dose finding and pharmacokinetic study. , 1990, British journal of clinical pharmacology.

[17]  W. Milhous,et al.  Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[18]  K. Rieckmann,et al.  PLASMODIUM VIVAX RESISTANCE TO CHLOROQUINE? , 1989, The Lancet.

[19]  N. White,et al.  Treatment of malaria: some considerations and limitations of the current methods of assessment. , 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[20]  A. Breckenridge,et al.  Pharmacokinetics of halofantrine in man: effects of food and dose size. , 1989, British journal of clinical pharmacology.

[21]  K. Miller,et al.  Chloroquine treatment of severe malaria in children. Pharmacokinetics, toxicity, and new dosage recommendations. , 1988, The New England journal of medicine.

[22]  D. Kariuki,et al.  EFFICACY OF MULTIPLE-DOSE HALOFANTRINE IN TREATMENT OF CHLOROQUINE-RESISTANT FALCIPARUM MALARIA IN CHILDREN IN KENYA , 1988, The Lancet.

[23]  M. Molyneux,et al.  CLINICAL TRIALS WITH HALOFANTRINE HYDROCHLORIDE IN MALAWI , 1988, The Lancet.

[24]  N. White,et al.  Single dose phenobarbitone prevents convulsions in cerebral malaria , 1988, The Lancet.

[25]  K. Silamut,et al.  Quinine pharmacokinetics in cerebral malaria: predicted plasma concentrations after rapid intravenous loading using a two-compartment model. , 1988, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[26]  R. Howells,et al.  Chlorproguanil/dapsone for the treatment of non-severe Plasmodium falciparum malaria in Kenya: a pilot study. , 1988, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[27]  N. White,et al.  Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects. , 1987, British journal of clinical pharmacology.

[28]  R. Howells,et al.  A preliminary pharmacokinetic study of the antimalarial drugs, proguanil and chlorproguanil , 1987, The Journal of pharmacy and pharmacology.

[29]  N. White.  COMBINATION TREATMENT FOR FALCIPARUM PROPHYLAXIS , 1987, The Lancet.

[30]  N. White,et al.  Parenteral chloroquine for treating falciparum malaria. , 1987, The Journal of infectious diseases.

[31]  Y. Zhang,et al.  Stage-dependent inhibition of chloroquine on Plasmodium falciparum in vitro. , 1986, The Journal of parasitology.

[32]  R. Stern,et al.  Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis. , 1986, The American journal of tropical medicine and hygiene.

[33]  A. Proudfoot,et al.  Death and blindness due to overdose of quinine. , 1985, British medical journal.

[34]  K. Silamut,et al.  Binding of quinine to plasma proteins in falciparum malaria. , 1985, The American journal of tropical medicine and hygiene.

[35]  N. White,et al.  Intravenous quinidine for the treatment of severe falciparum malaria. Clinical and pharmacokinetic studies. , 1985, The New England journal of medicine.

[36]  N. White.  Clinical Pharmacokinetics of Antimalarial Drugs , 1985, Clinical pharmacokinetics.

[37]  J. Henry,et al.  COMPLICATIONS OF QUININE POISONING , 1985, The Lancet.

[38]  A. Breckenridge,et al.  Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite. , 1984, British journal of clinical pharmacology.

[39]  G. Alván,et al.  Plasma chloroquine and desethylchloroquine concentrations in children during and after chloroquine treatment for malaria. , 1983, British journal of clinical pharmacology.

[40]  J. Jensen,et al.  Stage-dependent effects of chloroquine on Plasmodium falciparum in vitro. , 1983, The Journal of protozoology.

[41]  K. Silamut,et al.  Quinine disposition kinetics. , 1983, British journal of clinical pharmacology.

[42]  R. Turner,et al.  Severe hypoglycemia and hyperinsulinemia in falciparum malaria. , 1983, The New England journal of medicine.

[43]  K. Silamut,et al.  Red cell quinine concentrations in falciparum malaria. , 1983, The American journal of tropical medicine and hygiene.

[44]  B. Beermann,et al.  Disposition of chloroquine in man after single intravenous and oral doses. , 1983, British journal of clinical pharmacology.

[45]  A. Sabchareon,et al.  Serum quinine concentrations following the initial dose in children with falciparum malaria. , 1982, The Southeast Asian journal of tropical medicine and public health.

[46]  N. White,et al.  Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria. , 1982, The American journal of medicine.

[47]  G. Li,et al.  Clinical studies on treatment of cerebral malaria with qinghaosu and its derivatives. , 1982, Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan.

[48]  D. Warrell,et al.  Dexamethasone proves deleterious in cerebral malaria. A double-blind trial in 100 comatose patients. , 1982, The New England journal of medicine.

[49]  T. Chongsuphajaisiddhi,et al.  In vivo and in vitro sensitivity of Falciparum malaria to quinine in Thai children. , 1981, Annals of tropical paediatrics.

[50]  K. Barry,et al.  Kinetics of a new antimalarial, mefloquine , 1979, Clinical pharmacology and therapeutics.

[51]  C. D. Hufford,et al.  Metabolism of antimalarial sesquiterpene lactones. , 1990, Pharmacology & therapeutics.

[52]  G. Cook.  Practical chemotherapy of malaria. Report of a WHO Scientific Group. , 1990, World Health Organization technical report series.

[53]  A. Fleming.  Opportunistic infections in AIDS in developed and developing countries. , 1990, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[54]  R. Steketee,et al.  Mefloquine therapy for Plasmodium falciparum malaria in children under 5 years of age in Malawi: in vivo/in vitro efficacy and correlation of drug concentration with parasitological outcome. , 1990, Bulletin of the World Health Organization.

[55]  Severe and complicated malaria. World Health Organization, Division of Control of Tropical Diseases. , 1990, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[56]  U. Hellgren,et al.  Response of Plasmodium falciparum to chloroquine treatment: relation to whole blood concentrations of chloroquine and desethylchloroquine. , 1989, Bulletin of the World Health Organization.

[57]  A. Breckenridge,et al.  The disposition of amodiaquine in man after oral administration. , 1987, British journal of clinical pharmacology.

[58]  Ya Zhang,et al.  STAGE-DEPENDENT INHIBITION OF CHLOROQUINE ON , 1986 .

[59]  N. White,et al.  Quinine loading dose in cerebral malaria. , 1983, The American journal of tropical medicine and hygiene.